Intrathecal administration of netilmicin in gentamicin-resistant ventriculitis.
In ventriculitis caused by Gentamicin-resistant staphylococcus aureus and staphylococcus epidermidis, Netilmicin was administered intrathecally to 19 patients under continuous control of the Netilmicin concentration in cerebro-spinal fluid (CSF). This therapy was able to bring these otherwise lethal infections under control, usually within 10 days. Pharmacokinetic studies with different doses have shown that doses of 2 X 3 mg are to be recommended in moderately severe cases of ventriculitis, and in most severe infections 3 X 3 mg daily intraventricularly for adults. In infants daily intraventricular injections of 2 X 0.4-0.5 mg Netilmicin are a sufficient dose to produce an effective antibiotic concentration level.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002404:Catheterization; D002552:Cerebral Ventricles; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial; D004660:Encephalitis / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D008297:Male; D008875:Middle Aged; D009428:Netilmicin / Q000008:administration & dosage* / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy*
D005839:Gentamicins; D009428:Netilmicin